News >

Emerging Developments in NETs, Liver Cancer

Chelsea LoCascio
Published: Tuesday, Nov 21, 2017

I would also argue that it is not just the refractory patients. We are trying get [patients] on active agents in combination for frontline studies, as well. To finally see some smoke around the fires that are there in some active drugs, we're trying to get people into more active areas of research—earlier rather than later. 

What else about this talk do you think is important to mention?

We talked about biliary cancers, [which are] traditionally underserved and ignored. The BILCAP data, which demonstrated a positive adjuvant study for biliary cancers with the addition of capecitabine versus observation, was important. While the results weren’t overwhelming, these studies have been done a number of times and had not shown dramatic or positive results with gemcitabine plus oxaliplatin.

We are also seeing those biliary cancers being broken up into baskets, at least in the refractory setting beyond gemcitabine and cisplatin. We are starting to see FGFR-targeted agents and IDH inhibitors show activity. This is a disease that, molecularly, if there is enough tissue that we can look at, there are some options that are active for those patients. I would very much encourage clinical trial participation, because the second- and third-line settings do not perform well for those patients. We do not have a lot of data to support active regimens there.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Briefings™: Overcoming Chronic Iron Overload in Pediatric AML and MDSJun 30, 20181.0
Community Practice Connections™: New Frontiers in Immuno-Oncology for Microsatellite Instability-High CancersAug 29, 20182.0
Publication Bottom Border
Border Publication